m-iodobenzylguanidine γ-scintigraphy
The iodobenzyl bromide γ-scintillation is carried out by the following principle: iodobenzyl bromide is an anti-adrenergic neuron agent that takes up an amine substrate and, after injection into the body, concentrates on the adrenal medulla and In pheochromocytoma, gamma scintigraphy is used to visualize the single or multiple pheochromocytoma in the body. Basic Information Specialist classification: urinary examination classification: other examinations Applicable gender: whether men and women apply fasting: not fasting Tips: Forbidden to pay attention to normal diet before check, pay attention to normal work and rest, prevent endocrine disorders. Normal value Normal people develop salivary glands, liver, spleen and bladder 24 and 48 hours after injection. A few people also have iodobenzyl bromide in the heart and colon, and 80% of the adrenal glands are not developed. Types I and II belong to normal adrenal imaging. Type III is abnormal imaging. Clinical significance Imidazolium gamma-gamma photography provides an important method for the diagnosis and localization of pheochromocytoma. The principle is that MIBG is chemically similar to norepinephrine and can be taken up by adrenal medulla and pheochromocytoma. Therefore, it is specific for pheochromocytoma examination and can identify whether the tumor in other parts of the adrenal gland or adrenal gland is pheochromocytoma. It has the advantages of safety, specificity and high accuracy. Abnormal results: The clinical manifestations of pheochromocytoma vary widely from asymptomatic and physical signs to sudden onset of malignant hypertension, heart failure or cerebral hemorrhage. PHEO is "about 10% rule", that is, about 10% is outside the adrenal gland, 10% is malignant, 10% is familial, 10% is in children, 10% is bilateral, and 10% is multiple. Clinical signs and symptoms are associated with excessive secretion of catecholamines, the so-called "6H performance" hypertension (hypertension), headache (headache), heart consciousness (hypertension), hypermetabolism (hypermetabolism), hyperglycemia (hyperglycemia), hyperhidrosis (hyperhidrosis) . People who need to be examined: high blood pressure, heart failure, cerebral hemorrhage, high metabolic status, excessive sweating, excessive secretion of catecholamines, and other patients suspected of having pheochromocytoma. Precautions Forbidden before examination: pay attention to normal diet, pay attention to normal work and rest, and prevent endocrine disorders. Requirements for inspection: Actively cooperate with the doctor's request. Inspection process [method] 1. The patient received oral administration of Lugol's solution 3 days before the test, 3 times a day, 3 times a day until the 7th day after the start of the examination to close the thyroid gland. 2, m-iodobenzyl hydrazine physiological saline solution to calculate the required dose of 0.5 / 1.7 body surface area, slow intravenous injection. 3. Gamma scintigraphy was performed 24, 48, and 72 hours after the injection. The patient first examined the adrenal gland in the prone position, and then performed a full-body gamma photography from the head to the bladder in the supine position. [result] Normal people develop salivary glands, liver, spleen and bladder 24 and 48 hours after injection. A few people also have iodobenzyl bromide in the heart and colon, and 80% of the adrenal glands are not developed. The radioactive density of m-iodobenzidine in the adrenal gland can be classified into three types. Type I adrenal radiation density < liver; type II adrenal gland is equivalent to liver. III adrenal gland> liver. [Results analysis] According to the results of iodobenzyl 胍-scingraphy between patients, it is possible to determine whether there is a possibility of pheochromocytoma. Not suitable for the crowd Inappropriate crowd: temporarily unknown. Adverse reactions and risks No related complications or hazards.
The material in this site is intended to be of general informational use and is not intended to constitute medical advice, probable diagnosis, or recommended treatments.